Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma

References

• Coindre JM, Terrier P, Guillou L, Le Doussal V, Collin F, Ranchere D, Sastre X, Vilain MO, Bonichon F, N'Guyen Bui B. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 2001; 91:1914-26; PMID:11346874; http://dx.doi.org/10.1002/1097-0142(20010515)91:10%3c1914::AID-CNCR1214%3e3.0.CO;2-3
   PubMed Web of Science ®Google Scholar
• Hodgkinson DJ, Soule EH, Woods JE. Cutaneous angiosarcoma of the head and neck. Cancer 1979; 44:1106-13; PMID:573173; http://dx.doi.org/10.1002/1097-0142(197909)44:3%3c1106::AID-CNCR2820440345%3e3.0.CO;2-C
   PubMed Web of Science ®Google Scholar
• Brady A, Al-Kalbani M, Al Rawahi T, Nagar H, McCluggage WG. Postirradiation primary vaginal angiosarcoma with widespread intra-abdominal metastasis. Int J Gynecol Pathol 2011; 30:514-7; PMID:21804395; http://dx.doi.org/10.1097/PGP.0b013e318214bd05
   PubMed Web of Science ®Google Scholar
• Behranwala KA, A'Hern R, Omar AM, Thomas JM. Prognosis of lymph node metastasis in soft tissue sarcoma. Ann Surg Oncol 2004; 11:714-9; PMID:15231526; http://dx.doi.org/10.1245/ASO.2004.04.027
   PubMed Web of Science ®Google Scholar
• Fujisawa Y, Yoshino K, Kadono T, Miyagawa T, Nakamura Y, Fujimoto M. Chemoradiotherapy with taxane is superior to conventional surgery and radiotherapy in the management of cutaneous angiosarcoma: a multicentre, retrospective study. Br J Dermatol 2014; 171:1493-500; PMID:24814962; http://dx.doi.org/10.1111/bjd.13110
   PubMed Web of Science ®Google Scholar
• Ito T, Uchi H, Nakahara T, Tsuji G, Oda Y, Hagihara A, Furue M. Cutaneous angiosarcoma of the head and face: a single-center analysis of treatment outcomes in 43 patients in Japan. J Cancer Res Clin Oncol 2016; 142:1387-94; PMID:27015673; http://dx.doi.org/10.1007/s00432-016-2151-2
   PubMed Web of Science ®Google Scholar
• Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, Kerbrat P, Fournier C, Taieb S, Jimenez M et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol 2008; 26:5269-74; PMID:18809609; http://dx.doi.org/10.1200/JCO.2008.17.3146
   PubMed Web of Science ®Google Scholar
• Perez MC, Padhya TA, Messina JL, Jackson RS, Gonzalez RJ, Bui MM, Letson GD, Cruse CW, Lavey RS, Cheong D et al. Cutaneous angiosarcoma: a single-institution experience. Ann Surg Oncol 2013; 20:3391-7; PMID:23835652; http://dx.doi.org/10.1245/s10434-013-3083-6
   PubMed Web of Science ®Google Scholar
• Donghi D, Kerl K, Dummer R, Schoenewolf N, Cozzio A. Cutaneous angiosarcoma: own experience over 13 years. Clinical features, disease course and immunohistochemical profile. J Eur Acad Dermatol Venereol 2010; 24:1230-4; PMID:20236193; http://dx.doi.org/10.1111/j.1468-3083.2010.03624.x
   PubMed Web of Science ®Google Scholar
• Fury MG, Antonescu CR, Van Zee KJ, Brennan MF, Maki RG. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J 2005; 11:241-7; PMID:16053668; http://dx.doi.org/10.1097/00130404-200505000-00011
   PubMed Web of Science ®Google Scholar
• Fujii H, Arakawa A, Utsumi D, Sumiyoshi S, Yamamoto Y, Kitoh A, Ono M, Matsumura Y, Kato M, Konishi K et al. CD8(+) tumor-infiltrating lymphocytes at primary sites as a possible prognostic factor of cutaneous angiosarcoma. Int J Cancer 2014; 134:2393-402; PMID:24243586; http://dx.doi.org/10.1002/ijc.28581
   PubMed Web of Science ®Google Scholar
• Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, Okazaki T, Tokura Y. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010; 116:1757-66; PMID:20143437; http://dx.doi.org/10.1002/cncr.24899
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Mazieres J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 2015; 16:257-65; PMID:25704439; http://dx.doi.org/10.1016/S1470-2045(15)70054-9
   PubMed Web of Science ®Google Scholar
• Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372:311-9; PMID:25482239; http://dx.doi.org/10.1056/NEJMoa1411087
   PubMed Web of Science ®Google Scholar
• Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, Wu C, Zheng L. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med 2009; 206:1327-37; PMID:19451266; http://dx.doi.org/10.1084/jem.20082173
   PubMed Web of Science ®Google Scholar
• Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T, Gajewski TF. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 2004; 64:1140-5; PMID:14871849; http://dx.doi.org/10.1158/0008-5472.CAN-03-3259
   PubMed Web of Science ®Google Scholar
• Abiko K, Mandai M, Hamanishi J, Yoshioka Y, Matsumura N, Baba T, Yamaguchi K, Murakami R, Yamamoto A, Kharma B et al. PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin Cancer Res 2013; 19:1363-74; PMID:23340297; http://dx.doi.org/10.1158/1078-0432.CCR-12-2199
   PubMed Web of Science ®Google Scholar
• Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, Mizuno T, Yoriki R, Kashizuka H, Yane K et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 2005; 11:2947-53; PMID:15837746; http://dx.doi.org/10.1158/1078-0432.CCR-04-1469
   PubMed Web of Science ®Google Scholar
• Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 2007; 104:3360-5; PMID:17360651; http://dx.doi.org/10.1073/pnas.0611533104
   PubMed Web of Science ®Google Scholar
• Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, Nakamura S, Enomoto K, Yagita H, Azuma M et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007; 13:2151-7; PMID:17404099; http://dx.doi.org/10.1158/1078-0432.CCR-06-2746
   PubMed Web of Science ®Google Scholar
• Xu F, Xu L, Wang Q, An G, Feng G, Liu F. Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis. Int J Clin Exp Med 2015; 8:14595-603; PMID:26628942
   PubMed Web of Science ®Google Scholar
• Lipson EJ, Vincent JG, Loyo M, Kagohara LT, Luber BS, Wang H, Xu H, Nayar SK, Wang TS, Sidransky D et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res 2013; 1:54-63; PMID:24416729; http://dx.doi.org/10.1158/2326-6066.CIR-13-0034
   PubMed Web of Science ®Google Scholar
• Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, Kwon ED. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 2007; 13:1757-61; PMID:17363529; http://dx.doi.org/10.1158/1078-0432.CCR-06-2599
   PubMed Web of Science ®Google Scholar
• Muenst S, Hoeller S, Dirnhofer S, Tzankov A. Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival. Hum Pathol 2009; 40:1715-22; PMID:19695683; http://dx.doi.org/10.1016/j.humpath.2009.03.025
   PubMed Web of Science ®Google Scholar
• Hsu MC, Hsiao JR, Chang KC, Wu YH, Su IJ, Jin YT, Chang Y. Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma. Mod Pathol 2010; 23:1393-403; PMID:20657553; http://dx.doi.org/10.1038/modpathol.2010.130
   PubMed Web of Science ®Google Scholar
• Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N, Levionnois E, Nizard M, Si-Mohamed A, Besnier N et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013; 73:128-38; PMID:23135914; http://dx.doi.org/10.1158/0008-5472.CAN-12-2606
   PubMed Web of Science ®Google Scholar
• Sauce D, Almeida JR, Larsen M, Haro L, Autran B, Freeman GJ, Appay V. PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status. AIDS 2007; 21:2005-13; PMID:17885290; http://dx.doi.org/10.1097/QAD.0b013e3282eee548
   PubMed Web of Science ®Google Scholar
• Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007; 13:84-8; PMID:17159987; http://dx.doi.org/10.1038/nm1517
   PubMed Web of Science ®Google Scholar
• Mandai M, Hamanishi J, Abiko K, Matsumura N, Baba T, Konishi I. Dual Faces of IFNgamma in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity. Clin Cancer Res 2016; 22:2329-34; PMID:27016309; http://dx.doi.org/10.1158/1078-0432.CCR-16-0224
   PubMed Web of Science ®Google Scholar
• Eppihimer MJ, Gunn J, Freeman GJ, Greenfield EA, Chernova T, Erickson J, Leonard JP. Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation 2002; 9:133-45; PMID:11932780; http://dx.doi.org/10.1080/713774061
   PubMed Web of Science ®Google Scholar
• M M. Angiosarcoma of the scalp: strategy and evaluation at Kitasato University Hospital. Skin Cancer (Jpn) 2009; 24:377-84; http://dx.doi.org/10.5227/skincancer.24.377
   Google Scholar
• Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4:127ra37; PMID:22461641; http://dx.doi.org/10.1126/scitranslmed.3003689
   PubMed Web of Science ®Google Scholar
• Hoshina D, Abe R, Yoshioka N, Saito N, Hata H, Fujita Y, Aoyagi S, Shimizu H. Establishment of a novel experimental model of human angiosarcoma and a VEGF-targeting therapeutic experiment. J Dermatol Sci 2013; 70:116-22; PMID:23522954; http://dx.doi.org/10.1016/j.jdermsci.2013.02.008
   PubMed Web of Science ®Google Scholar
• Masuzawa M, Fujimura T, Hamada Y, Fujita Y, Hara H, Nishiyama S, Katsuoka K, Tamauchi H, Sakurai Y. Establishment of a human hemangiosarcoma cell line (ISO-HAS). Int J Cancer 1999; 81:305-8; PMID:10188735; http://dx.doi.org/10.1002/(SICI)1097-0215(19990412)81:2%3c305::AID-IJC22%3e3.0.CO;2-Z
   PubMed Web of Science ®Google Scholar
• Masuzawa M, Fujimura T, Tsubokawa M, Nishiyama S, Katsuoka K, Terada E, Kunita S, Sakurai Y, Kato H. Establishment of a new murine-phenotypic angiosarcoma cell line (ISOS-1). J Dermatol Sci 1998; 16:91-8; PMID:9459120; http://dx.doi.org/10.1016/S0923-1811(97)00032-7
   PubMed Web of Science ®Google Scholar